This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 315| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2580 | Dystrophin, Homolog to tubulin beta chain, Zinc finger protein 337, Friedreich ataxia region gene X123, Fibronectin (Alt. Splice 1), Zinc finger protein 9, Metallothionein IV, Poly(rC) binding protein 3, KIAA0426 gene product, Hypothetical protein FLJ13910, RAN binding protein 2 like 1, S100 calcium | RNAs | Human | Downregulated in L1 than L0 (with fisher ratio more than 9.74) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2581 | Cystatin C, Prolylcarboxypeptidase (angiotensinase C), Lysyl-tRNA synthetase, Voltage-dependent anion channel 3, Protective protein for beta-galactosidase (cathepsin A), Interferon gamma-inducible protein 30, Signal sequence receptor delta, Thioredoxin-related transmembrane protein, Cathepsin D, Ras | RNAs | Human | Upregulated in L1 than L0 (with Fisher ratio more than 8.9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2582 | Mannose receptor C type 1, BCL2/adenovirus E1B 19 kD interacting protein 3 like, v-fos FBJ murine osteosarcoma viral oncogene homolog, Ficolin 3 (Hakata antigen), Calmodulin 1, v-maf musculoaponeurotic fibrosarcoma oncogene homolog, Metallothionein 1H, Metallothionein 1E, Solute carrier family 31 me | RNAs | Human | Downregulated in G1 than L1 (with fisher ratio more than 9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s G1 (well differentiated) HCV-HCC; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2583 | SNRPB, TBCE, DRAP1, UFD1L, MT4, ATP6V1E, calmodulin dependent protein kinase 2, ZFP103, ATOX1, Interleukin enhancer binding factor 2 | RNAs | Human | Upregulated in G1 than L1 (with fisher ratio more than 9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s G1 (well differentiated) HCV-HCC; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2584 | OAS2, ADH1A, FLJ20378, HSF2, PSME1, E2L6, UBE2L6, STAT1, LIM, FLN29, GABARAPL1, | RNAs | Human | Downregulated in G2 than G1 (with fisher ratio more than 1.7) | Prognostic | G1 (well differentiated) HCV-HCC v/s G2 (moderately differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2585 | RPNI, ZNF161, EIF4G1, FNBP3, CCT6A, PPIB, IMPA2, GORASP2, KIAA0669, ATP2A2, PA200, ZNF91, GOLGA4, KIAA0494, SIAH1, UBQLN2, ADNP, TPD52L2, FDPS, DICER1 | RNAs | Human | Upregulated in G2 than G1 (with fisher ratio more than 1.7) | Prognostic | G1 (well differentiated) HCV-HCC v/s G2 (moderately differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2586 | APOC1, SEPP1, PDZGEF1, SCML2, ALDH5A1, BNIP3, FBXW1B, PAH, Homo sapiens clone 24473 mRNA sequence, PACE4, FLJ31305 fis or clone LIVER1000104 or , Unknown or , MIG2, RARRES2, BAAT, KDELR2, RNP24, FACL2, KIAA0977 protein, HADHSC, HADHSC, SDHD, CPB2, PGRMC1, AOP2, PPM1A, SDC1, CCL14, EST | RNAs | Human | Downregulated in G3 compared with G2 (with Fisher ratio more than 1.3) | Prognostic | G2 (moderately differentiated) HCV-HCC v/s G2 (poorly differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2587 | DAZAP2, SPINT1, LGALS9, CYBA, BAZ2A, PPT1, S100A13, LGALS9, PIM2, TGFB1 | RNAs | Human | Upregulated in G3 compared with G2 (with Fisher ratio more than 1.3) | Prognostic | G2 (moderately differentiated) HCV-HCC v/s G2 (poorly differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2588 | NM23-H2,MCM7, PARP1, YWHAH, HSPB1, MSH2 | RNAs | Human | Upregulated in tumor | Diagnostic | HCC v/s non-tumor | P<0.001 | Tissue | 16703398 |
| 2589 | MT1A, MT3 | RNAs | Human | downregulated in tumor | Diagnostic | HCC v/s non-tumor | P<0.001 | Tissue | 16703398 |
| 2590 | MPV17, EST, GZMB, ITGA6, EST, CENPC1, EST, SPP1, RTF1, CYB5-M, P4HA2, DNMBP, EST, DNAJB4, PRH1, STK23, TCF2, POSTN, SPP1, WIZ, OSMR, EST, ILIA, CD44, EST, MUC6, MTHFD2, ANXA2, PCSK2, RBP1, EST, ITGA6, APRT, PDUM3, TPM2, RNASE3, OSMR, GRK1, SLC14A, FETUB, ANXA2P1, UGT2B15, EST, KIAA0703, AKAP10, AVPR | RNAs | Human | Genes associated with EHR of HCC | Prognostic | Extrahepatic recurrence (EHR) v/s Early intrahepatic recurrence (IHR) | P< 0.05 | Tissue | 17016605 |
| 2591 | ITGA6, SPP1, DNMBP, CD44, POSTN | RNAs | Human | Upregulated in HCC with EHR than in HCC without EHR. | Prognostic | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. | P< 0.05 | Tissue | 17016605 |
| 2592 | ITGA6, SPP1 | RNAs | Human | Upregulated in HCC with EHR than HCC without EHR and non-cancerous liver tissue ( also higher expression in HCC without EHR than non-cancerous liver tissue) | Prognostic | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. | P< 0.05 | Tissue | 17016605 |
| 2593 | DNMBP, CD44, POSTN | RNAs | Human | Upregulated in HCC with EHR than HCC without EHR and non-cancerous liver tissue ( but similar expression in HCC without EHR and non-cancerous liver tissue) | Prognostic | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. | P< 0.05 | Tissue | 17016605 |
| 2594 | GZMB, IL1A, | RNAs | Human | Downregulated in HCC with EHR than HCC without EHR and non-cancerous liver tissue | Prognostic | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. | P< 0.05 | Tissue | 17016605 |